潜在首款!降低疾病指标近100%,再生元单抗上市申请递交在即再生元(Regeneron Pharmaceuticals)今日宣布,其在研疗法garetosmab用于治疗成人进行性骨化性纤维发育不良(FOP)的3期OPTIMA研究达到主要终点。该疗法能够显著减少新生异位骨化(HO)病灶的数量与体积。公司计划于2025年年底前向美国FDA提交相关监管申请。根据新闻稿,garetosmab为在成人FOP...
Source Link潜在首款!降低疾病指标近100%,再生元单抗上市申请递交在即再生元(Regeneron Pharmaceuticals)今日宣布,其在研疗法garetosmab用于治疗成人进行性骨化性纤维发育不良(FOP)的3期OPTIMA研究达到主要终点。该疗法能够显著减少新生异位骨化(HO)病灶的数量与体积。公司计划于2025年年底前向美国FDA提交相关监管申请。根据新闻稿,garetosmab为在成人FOP...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.